Hindu Business Line “Gilead’s patent application has been opposed on the grounds that it is an “old science, known compound,” said Tahir Amin, lawyer and director of US-based I-MAK.org. “India’s patent law doesn’t give monopolies for old science or for compounds that are already in the public domain. We believe this patent on sofosbuvir does not deserve to be granted in India and have the legal grounds to prove it,” he said in a statement by international humanitarian organisation MSF (Médecins Sans Frontières – Doctors without Borders), who support the patent opposition.
Partner with us now to build a more just and equitable medicine system for all. Notice: JavaScript is required for this content.